Healthcare / BiotechnologyNasdaqCM
$1.27
-0.08 (-5.93%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 24%
FCF escenarios
weak_data · normalized FCF $-7.3M · quality 61.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
21/100
D
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$63M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-87.3%
↓Gross Margin
N/A
•Debt/Equity
0.04
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2020–2025 · 5 años de histórico normalizado
Revenue CAGR
-35.1%
FCF CAGR
—
FCF margin
-17802.4%
FCF / Net income
0.65x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $42000.0 · net income $-11.4M · FCF $-7.5M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Revenue | $42000.00 | $42000.00 | $181000.00 | — | $134000.00 | $571000.00 | $365000.00 |
| Net Income | $-11.4M | $-11.4M | $-9.5M | $-8.9M | $-13.1M | $-12.2M | $-11.2M |
| EBITDA | $-11.5M | $-11.5M | $-9.5M | $-8.8M | $-13.0M | — | — |
| EPS | -0.25 | -0.25 | -0.25 | -0.31 | -0.45 | 0.47 | — |
| Gross Margin | — | — | 5.0% | — | 24.6% | 34.7% | 17.8% |
| Operating Margin | -27450.0% | -27450.0% | -5295.6% | — | -9714.2% | -2139.6% | -3059.7% |
| Net Margin | -27235.7% | -27235.7% | -5271.3% | — | -9754.5% | -2134.3% | -3072.9% |
| Balance Sheet | |||||||
| Debt/Equity | 0.04 | 0.04 | 0.03 | 0.04 | 0.01 | — | — |
| Current Ratio | 7.93 | 7.93 | — | — | — | — | — |
| Cash Flow | |||||||
| Free Cash Flow | $-7.5M | $-7.5M | $-6.8M | $-7.3M | $-12.5M | $-9.1M | $-10.6M |
| Returns | |||||||
| ROE | -87.3% | -87.3% | -118.1% | -85.6% | -111.2% | -54.0% | -149.3% |
| Valuation | |||||||
| P/B | 4.48 | 4.48 | 12.53 | 1.89 | 2.57 | — | — |
| Growth & Yield | |||||||
| Revenue Growth | -76.8% | -76.8% | — | — | — | 56.4% | — |
| EPS Growth | 0.0% | 0.0% | 19.4% | 31.1% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-31.2%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.25 → -0.25
Residual
-31.2%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.